Compare JPMorgan Equity Premium Income ETF (JEPI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs GeneDx Holdings Corp — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.79 (market cap $45.55B), while GeneDx Holdings Corp trades at $68.16 (market cap $2.02B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 22.5× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 3,820,809). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 57 Days and GeneDx Holdings Corp for 19 Days on average.
| JEPI | WGS | |
|---|---|---|
Market Cap | $45.55B | $2.02B |
Volume | 3,820,809 | 734,640 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $167.51 |
52-Week Low | $55.29 | $34.51 |
Typical Hold Time | 57 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.79, up 0.6% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators and key support at $56. Recent dividend activity includes three distributions averaging $0.36 per share through August-October 2026. Media coverage focuses on income generation strategies and tax implications for retirement portfolios.
The covered-call strategy provides consistent income but may limit upside during market rallies. Institutional interest remains strong with recent position increases. Key risks include interest rate sensitivity and the trade-off between yield and capital appreciation potential in rising markets.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
